BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BZE2204 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BZE2204\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07174843-5511@assetmemo.bio
DTSTAMP:20261121T004048Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:BZE2204: Phase 1 readout est. (NCT07174843)
DESCRIPTION:BZE2204\, phase 1\, Systemic Lupus Erythematosus.\nStudy: An Ex
 ploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With R
 elapsed or Refractory Autoimmune Diseases\nEstimated primary completion: A
 ugust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bze2204#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07174
 843
URL:https://assetmemo.bio/drug/bze2204#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
